8 orthobiologic updates

From new study findings to product launches, here are eight headlines to know in the orthobiologics space since Jan. 13:

Advertisement

1. Royal Biologics and Fair Winds Medical partnered to distribute spine and orthopedic biologics.

2. SurGenTec earned FDA 510(k) clearance for its OsteoFlo HydroFiber to be used as a stand-alone equivalent to autografts in spine surgeries.

3. LifeNet Health and Johnson & Johnson MedTech launched the PliaFX Flo demineralized bone matrix.

4. Acuitive Technologies named Wayne Berberian, MD, as its chief medical officer.

5. Jamie Antoine, MD, of Seattle-based Proliance Surgeons performed the first case using CartiHeal’s Agili-C implant in Washington state.

6. Stem cell therapies can be effective for treating discogenic low back pain, according to a study published in the January 2025 issue of the International Journal of Spine Surgery.

7. The global spine biologics market is on pace to have a 17.51% compound annual growth rate from 2024 to 2034.

8. Paul Fleissner, MD, of Fairlawn, Ohio-based Crystal Clinic Orthopaedic Center is the first surgeon to use the RejuvaKnee implant for meniscus repair.

Advertisement

Next Up in Biologics

Advertisement